CJC-1295 + Ipamorelin: Protocol and Evidence in Regenerative Medicine

What CJC-1295 and Ipamorelin actually are

CJC-1295 and Ipamorelin are two of the most discussed peptides in the growth hormone (GH) conversation, and they almost always appear together. They are not interchangeable, and they are not the same molecule as growth hormone itself. They are growth hormone secretagogue peptides, meaning they prompt your own pituitary gland to release the GH it is already capable of producing.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends to the pituitary. CJC-1295 exists in two formulations that are routinely confused, including in marketing copy. The original "CJC-1295 with DAC" (Drug Affinity Complex) was designed to bind to plasma albumin, giving it a long half-life of roughly six to eight days and producing a sustained elevation of GH and IGF-1. The more commonly prescribed form in clinical practice today, often called "CJC-1295 without DAC" or Modified GRF (1-29), is a 29-amino-acid GHRH fragment with a half-life of around thirty minutes. The short half-life is, counterintuitively, a feature: it preserves the body's natural pulsatile pattern of GH release rather than flattening it.

Ipamorelin is a pentapeptide ghrelin receptor agonist, in the same family of "GHRPs" (growth hormone-releasing peptides) as GHRP-2 and GHRP-6, but considerably more selective. Where older GHRPs also stimulate cortisol, prolactin, and appetite, Ipamorelin acts almost exclusively on the GH-release pathway, which is why it largely replaced its predecessors in clinical protocols.

Used together, CJC-1295 and Ipamorelin work on two different receptors in the pituitary and produce a synergistic, amplified GH pulse. This is the "CJC-1295 Ipamorelin" stack that has become the default growth hormone secretagogue peptides protocol in regenerative medicine clinics worldwide.

How the stack actually works

The conventional way to elevate GH levels in adults has been recombinant human growth hormone (rhGH), administered as a daily exogenous injection. rhGH bypasses the pituitary entirely and replaces the hormone directly, which works but has a meaningful clinical cost: it suppresses the pituitary feedback loop, requires careful IGF-1 monitoring, and produces a flat, non-physiologic exposure profile.

The CJC-1295 + Ipamorelin approach is mechanistically different. By stimulating the pituitary through two complementary receptors, GHRH and ghrelin, the stack triggers the body's own GH release while preserving the pulsatile rhythm. In healthy adults, GH is released in discrete pulses, primarily during the first hours of deep sleep. Restoring or amplifying those pulses, rather than overriding them, is the rationale for choosing a secretagogue protocol over exogenous GH.

The downstream effects of an elevated GH pulse are well-characterized in endocrinology: increased hepatic IGF-1 production, lipolysis in adipose tissue, support for lean muscle protein synthesis, and modulation of slow-wave sleep architecture. Whether peptide-induced GH pulses translate into clinically meaningful changes in body composition, recovery, and sleep in otherwise healthy adults is a separate question, and the honest answer is the subject of the next section.

What the clinical evidence shows

The published evidence for CJC-1295 and Ipamorelin is uneven, and it is worth being precise about what we know and where the data thin out.

CJC-1295 (with DAC) pharmacokinetics. The 2006 pharmacokinetic and pharmacodynamic studies of CJC-1295 with DAC in healthy adults are the cleanest data we have. They demonstrate dose-dependent, sustained elevations of GH and IGF-1 over multiple days after a single dose. This is mechanism-confirming evidence that the molecule does what it is designed to do.

Ipamorelin clinical evidence. Ipamorelin has been studied in several clinical contexts, including a Phase 2B trial for postoperative ileus, where it failed to meet its primary endpoint, and earlier work demonstrating selective GH release without significant cortisol or prolactin effect. The selective receptor profile is well-established. What is less established is whether Ipamorelin produces clinically meaningful outcomes in non-deficient adults seeking recovery, sleep, or body composition benefits.

The combination protocol. Here the published evidence is thinner than the marketing suggests. Most of what supports the "CJC-1295 + Ipamorelin" combination comes from mechanism plausibility, pharmacokinetic modeling, small open-label series, and clinical experience, rather than from large randomized controlled trials in healthy adults. Anti-aging and recovery claims are largely extrapolated from GH and IGF-1 physiology, not directly from head-to-head trials of this specific stack.

Peptide therapy for recovery sleep. The link between GH pulses and slow-wave sleep is biologically real, and some patients on secretagogue protocols report subjectively better sleep quality. This is a reasonable expectation based on physiology, but it is not the same as a placebo-controlled trial demonstrating sleep architecture changes from this specific protocol.

The honest summary, as of 2026, is that the CJC-1295 + Ipamorelin stack rests on strong mechanistic logic, well-characterized component pharmacology, and a real but limited body of clinical outcome data. It is reasonable to consider in selected patients within a supervised plan. It is not appropriate to present as a validated anti-aging therapy with established outcomes.

For broader context on how this peptide fits among others, our beginner's guide to peptide therapy covers the landscape, and our discussion of BPC-157 evidence in 2026 applies the same evidentiary discipline to a different molecule.

Typical dosing and protocol structure

Specific dosing belongs in a physician's office, not in a blog post, and any protocol described here is illustrative rather than prescriptive. That said, the general structure of a GH peptide protocol Mexico clinics use looks like this:

• Route. Subcutaneous injection, typically rotating between abdomen and thigh sites. Some compounding pharmacies offer combined CJC-1295/Ipamorelin in a single vial; others dispense them separately to allow individualized titration.
• Timing. Because endogenous GH pulses occur during deep sleep, the most common dose is administered at bedtime on an empty stomach. A meal, especially one containing carbohydrates or fat, blunts the GH response.
• Dose range. Published clinical and compounding-pharmacy protocols commonly use Ipamorelin in the range of 100 to 300 micrograms per dose, and Modified GRF (1-29) in a comparable microgram range. CJC-1295 with DAC, when used, is dosed weekly rather than nightly because of its long half-life.
• Cycle structure. Most clinicians use cyclical dosing, for example five nights on and two nights off, or eight to twelve week cycles followed by a washout, to preserve pituitary responsiveness and avoid receptor desensitization.
• Monitoring. Baseline and follow-up labs typically include IGF-1, fasting glucose, HbA1c, lipid panel, and thyroid function. IGF-1 in particular is the most useful surrogate for whether the protocol is producing a biological effect and whether it is staying within a physiologic range.

What no responsible protocol looks like: a flat dose for everyone, no labs, no follow-up, no contraindication screening, and no conversation about expectations. If that is what is being offered, it is not clinical peptide therapy.

Contraindications and who should not take this

Growth hormone pathways touch many systems, which is precisely why GH secretagogue peptides require screening before prescription. The categories where CJC-1295 and Ipamorelin are contraindicated or require special caution include:

• Active or recent malignancy. Elevated IGF-1 has been associated with growth of certain tumor types. Active cancer, recent cancer treatment, or strong personal or family history requires careful oncology input before any GH-axis intervention is considered.
• Pregnancy and breastfeeding. No safety data exist in these populations and the protocol is not appropriate.
• Pediatric and adolescent patients. GH secretagogues are not appropriate for healthy growing patients outside of a pediatric endocrinology context. Children and adolescents with diagnosed GH deficiency are managed by specialists with rhGH, not by regenerative clinics with secretagogue peptides.
• Diabetes and impaired glucose tolerance. GH is counter-regulatory to insulin. Patients with type 2 diabetes, pre-diabetes, or impaired fasting glucose require careful endocrine assessment, and many are not appropriate candidates.
• Active diabetic retinopathy. GH and IGF-1 elevation can worsen proliferative retinopathy.
• Untreated thyroid disease, severe sleep apnea, or known pituitary pathology. Each requires evaluation and stabilization before any GH-axis manipulation.

Side effects in appropriate candidates are generally mild and dose-dependent: transient injection-site reactions, occasional flushing or lightheadedness shortly after dosing, vivid dreams, and water retention. Persistent paresthesias, joint discomfort, or rising fasting glucose are signals to reduce dose or stop, and reasons monitoring labs exist.

COFEPRIS regulation and the Mexican context

In Mexico, peptide therapy operates under a specific regulatory framework that is worth understanding before any patient agrees to a protocol. The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) regulates pharmaceutical substances and the clinical environments in which they are administered.

As of 2026, neither CJC-1295 nor Ipamorelin is a COFEPRIS-registered finished pharmaceutical product with an approved indication for anti-aging, recovery, or body composition. They are accessed through licensed compounding pharmacies operating under the *farmacia magistral* framework, the same framework that governs custom-formulated medications across many therapeutic categories.

In practice this means three things any Mexican patient should expect:

• A written prescription from a licensed Mexican physician after an in-person evaluation. Online direct-to-consumer sales of these peptides as "research chemicals" sit outside the standard of care, regardless of how the website is worded.
• Source documentation. A reputable compounding pharmacy provides Certificates of Analysis for each lot, documenting peptide identity, purity, and absence of endotoxin contamination. Your clinic should be able to show you these for the specific lot dispensed.
• A notified clinical setting. Administration, training in self-injection, and follow-up should take place within a COFEPRIS-notified clinical environment with documented informed consent that acknowledges the off-label, compounded nature of the therapy.

This is the regulatory posture we operate under at Regeneris Therapy, and it is the posture any patient should expect from any serious clinic offering GH peptide protocol Mexico services.

Who is a reasonable candidate

There is no universal candidate for GH secretagogue peptides, and there is no version of this conversation where the answer is "everyone over forty." Based on current evidence and our clinical experience, the patients most likely to be appropriate are:

• Adults in their late thirties through sixties with documented age-related decline in GH and IGF-1, a clinical picture that includes reduced recovery capacity, deteriorating sleep architecture, and changes in body composition that have not responded to first-line lifestyle interventions.
• Athletes and active adults in structured training and recovery programs who have optimized training load, sleep hygiene, and nutrition, and for whom a supervised secretagogue cycle is being considered as an adjunct rather than as a primary intervention.
• Patients in supervised longevity protocols who already have baseline labs, an established clinical relationship, and a clear plan for monitoring and discontinuation.

The patients for whom this is not appropriate are equally important to name: anyone seeking a quick fix instead of doing the work, anyone whose primary issue is undiagnosed sleep apnea or thyroid dysfunction, anyone with the contraindications listed above, and anyone whose expectations have been set by social media rather than by a physician.

Moving forward with clarity

CJC-1295 and Ipamorelin, used as a supervised stack in selected patients, are a reasonable tool within the regenerative medicine and longevity conversation. They are not a replacement for the boring fundamentals, sleep, training, nutrition, and stress management, that make any GH protocol either useful or pointless. Used responsibly, they support physiology already in motion. Used as a shortcut around the fundamentals, they will disappoint.

If you are considering peptide therapy in Cancún or elsewhere in Mexico, the right first step is a physician evaluation with appropriate labs, not a product order from an online vendor. You can reach our team through our contact page to schedule a consultation, or learn more about our peptide therapy services at /peptides/en. Our medical team is happy to discuss whether this protocol is appropriate for your specific clinical picture.

Related reading

• A Beginner's Guide to Peptide Therapy
• BPC-157 in Mexico: What We Know as of 2026
• Anti-Aging and Longevity in Regenerative Medicine